Soleno Therapeutics (SLNO) EBITDA: 2013-2017
Historic EBITDA for Soleno Therapeutics (SLNO) over the last 4 years, with Dec 2017 value amounting to -$5.2 million.
- Soleno Therapeutics' EBITDA fell 183.62% to -$5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.2 million, marking a year-over-year decrease of 17.49%. This contributed to the annual value of -$175.5 million for FY2024, which is 350.11% down from last year.
- Soleno Therapeutics' EBITDA amounted to -$5.2 million in Q4 2017, which was down 97.61% from -$2.6 million recorded in Q3 2017.
- Soleno Therapeutics' EBITDA's 5-year high stood at -$559,783 during Q4 2013, with a 5-year trough of -$5.2 million in Q4 2017.
- For the 3-year period, Soleno Therapeutics' EBITDA averaged around -$2.9 million, with its median value being -$2.8 million (2017).
- In the last 5 years, Soleno Therapeutics' EBITDA slumped by 254.68% in 2015 and then soared by 67.79% in 2017.
- Quarterly analysis of 5 years shows Soleno Therapeutics' EBITDA stood at -$559,783 in 2013, then plummeted by 229.72% to -$1.8 million in 2014, then slumped by 89.99% to -$3.5 million in 2015, then spiked by 47.73% to -$1.8 million in 2016, then plummeted by 183.62% to -$5.2 million in 2017.
- Its last three reported values are -$5.2 million in Q4 2017, -$2.6 million for Q3 2017, and -$3.0 million during Q2 2017.